AstraZeneca Selects AI-Generated CKD Target Under its Collaboration with BenevolentAI
Shots:
- AstraZeneca has selected a novel CKD target to advance to its drug development portfolio- making it the first AI-generated target from the collaboration to enter its portfolio
- In 2019- companies collaborated to discover new drugs for CKD and IPF
- The collaboration leverages AstraZeneca's scientific expertise and rich datasets with BenevolentAI's target identification platform to understand these two complex diseases' underlying mechanisms and identify new drug targets
Ref: PRNewswire | Image: AstraZeneca
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
